Rehabilitation program for allogeneic bone marrow transplant patients
Official title: A Type 1 Hybrid Effectiveness Implementation Trial of a Longitudinal Multidimensional Rehabilitation Program for Patients Undergoing Allogeneic Blood and Marrow Transplantation (CaRE4alloBMT)
Run by University Health Network, Toronto · NCT07457866 · Data updated 2026-11-12
This trial will test whether the CaRE-4-alloBMT rehab program helps adults having allogeneic bone marrow transplants recover better than usual care.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 208 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | June 30, 2028 |
| Study ends | August 30, 2028 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT07457866 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age >18) scheduled for allogeneic bone marrow transplant for a hematologic cancer who complete pre- and post-transplant care at Princess Margaret Cancer Centre, can access online study material, and understand English.
✕Probably not a fit
Patients who have comorbidities or musculoskeletal issues that preclude exercise, cannot access online materials, are being admitted for transplant within two weeks of assessment, or are enrolled in other interventional studies may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a pragmatic, two-arm randomized controlled trial comparing the CaRE-4-alloBMT rehabilitation program to usual care in adults undergoing allogeneic bone marrow transplant. Participants complete questionnaires and an initial assessment with a registered kinesiologist, then are randomized to the intervention or usual care. Outcomes include patient-reported measures and physiological assessments collected at baseline, hospital admission, discharge, and at 3 and 6 months post-discharge to capture real-world recovery. The trial emphasizes external validity to inform whether the program can be delivered in routine clinical practice.
Why it matters
Potential benefit: If successful, the program could speed physical recovery, improve quality of life, and reduce post-transplant complications for alloBMT patients.
How similar studies have gone: Exercise and prehabilitation programs in cancer populations have shown benefits for physical function and recovery, but robust phase‑III evidence specifically for allogeneic BMT patients is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: • scheduled to undergo alloBMT and are: * \> 18 years of age; * receiving treatment for a hematologic cancer; * completing pre- and post-transplant care at PM; * able to access on-line study material; and * able to understand (spoken and written) English. Participants receiving a second transplant at the time of screening will be included if they meet the above criteria. Exclusion Criteria: * scheduled to be admitted to the hospital for their alloBMT \< 2 weeks from the initial assessment booking, as this will not allow enough time for the prehabilitation phase of the study; * are participating in any other clinical trials or supportive care intervention studies; or * have comorbidities or musculoskeletal complications that preclude participation in the exercise programs.
Where it's running
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Jennifer M Jones, PhD — UHN Princess Margaret Cancer Centre
- Study coordinator: Jennifer M Jones, PhD
- Email: Jennifer.jones@uhn.ca
- Phone: 14165818603
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving Sleep for Older Adults in the Emergency Department
This project tests whether wearing a Fitbit overnight can help understand and improve sleep for adults 70 and older in the emergency department who are likely to be admitted.
-
Can miRNA-371a-3p tell us which small testicular masses need surgery or can be watched?
This study tests whether the miRNA-371a-3p biomarker can help decide if small testicular masses (≤2 cm) are cancer and should be treated with surgery or followed with surveillance.
-
Effects of excitatory and inhibitory LIFUS of GPi in Parkinson’s patients without DBS
This study tests two deep-brain focused ultrasound patterns on people with Parkinson’s to see if they change task performance and tremor, compared with a sham stimulation.
-
Co-Adaptation of a Digital Pain Program for Canadian Veterans
We’re testing whether a self-guided digital pain management program, delivered through the Manage My Pain app, is acceptable and useful for Canadian Veterans with chronic pain.
-
Vagina-View helps guide multichannel applicator placement during vaginal brachytherapy
This study tests whether the Vagina-View device can visualize vaginal tumors and help place the MCA more precisely during brachytherapy for vaginal cancer.
-
Isunakinra Plus Pembrolizumab Neoadjuvant Therapy for TNBC
This trial tests whether adding isunakinra to pembrolizumab-based neoadjuvant chemotherapy can help treat newly diagnosed, locally advanced triple-negative breast cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.